Earnings

IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial

Sep 24, 2026 · 08:10 AM ET· updated 1h ago

2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout in OVATION

Why It Matters

Imunon shared positive survival results from its cancer study. This progress suggests the company's treatment is working as hoped.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IMNN1.39

-0.08 (-5.78%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.